# OnCo record fhd-909 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/fhd-909/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "fhd-909" ;
  schema:name "FHD-909"@en ;
  schema:alternateName "LY4050784"@en ;
  schema:description "FHD-909 is an oral small-molecule allosteric inhibitor from Foghorn Therapeutics that reached phase 1 for SMARCA4-mutant non-small cell lung cancer and SMARCA4-deficient solid tumours; development has stopped."@en ;
  schema:url <https://onco.cc/drugs/fhd-909/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.sec.gov/Archives/edgar/data/1822462/000162828026064102/exhibit991foghornpressrele.htm>, <https://www.sec.gov/Archives/edgar/data/1822462/000162828026064102/exhibit991foghornpressrele.htm>, <https://clinicaltrials.gov/search?intr=FHD-909> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest", "discontinued" ;
  onco:modality "Oral small-molecule allosteric inhibitor" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:targets <https://onco.cc/targets/smarca2/> ;
  onco:companies <https://onco.cc/companies/foghorn-therapeutics/> ;
  onco:trials <https://onco.cc/trials/nct06561685/> .